Sanofi and Regeneron Biologic Drug Dupixent Notches a New FDA Approval in COPD

MedCity News September 29, 2024
Frank Vinluan

Dupixent, a Sanofi and Regeneron Pharmaceuticals drug, is now approved for chronic obstructive pulmonary disease (COPD), a progressive lung disease prevalent in smokers. It’s the sixth FDA-approved indication for the blockbuster drug.

The blockbuster Sanofi and Regeneron Pharmaceuticals drug Dupixent, already commercialized in several skin and lung disorders, has expanded its FDA-approval to chronic obstructive pulmonary disease (COPD), a progressive lung condition prevalent in smokers.

The regulatory decision announced Friday permits Dupixent’s use as an add-on maintenance treatment of adults whose COPD is inadequately controlled by available therapies. The every-other-week injectable drug is now the first biologic therapy approved by the FDA for treating COPD.

In COPD, damage to the lungs leads to inflamed airways that cause breathing difficulty, coughing,...

Today's Sponsors

Today's Sponsor